Tim Shannon

BioWorld Insider Podcast: Better Times Ahead for the Biopharma Sector? Could be, the New Numbers Say

Endpoints News: Pfizer bets $1B cash on the original protein degraders as technology nears prime time

Fierce Biotech: Biotech Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table

Fierce Biotech: Rallybio hires Tuch from BMO to lead corporate development

Fierce Biotech: Ideaya, Spelman College team up to provide young African American women a stepping stone to biotech careers

Endpoints News: Vivace Therapeutics scores $30M Series C to take oncology candidate for 'Hippo' pathway to human trial next year

Fierce Biotech: Vivace snares $30M to push Hippo-targeting drugs into the clinic

FierceBiotech: Arvinas eyes a busy 2021 as protein degraders gather steam in breast, prostate cancers

Endpoints News: Billions on the table, GSK’s Hal Barron antes $120M cash to partner with Ideaya

Fierce Biotech: GlaxoSmithKline pens $120M upfront synthetic lethality cancer pact with Fierce 15 winner Ideaya

MedCity News: GSK pumps $120M into partnership with Ideaya in oncology precision medicine play

BioCentury: With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

FierceBiotech: Rallybio scores $145M, unveils lead rare disease program

FierceBiotech: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer

BioCentury: Beyond PROTACs and the proteasome - broadening the TAC toolbox

Wired: These protein picker-uppers keep your cells clean and healthy

Endpoints News: Bayer enlists Arvinas on two-pronged protein degradation effort, foraying into agtech

Tim Shannon in BioCentury: Making orphan drug prices work for society

Endpoints News: Four biotechs, including NextCure, haul in $303M+ from a fresh burst of IPOs

Business Insider: Scientists are working on cancer treatments that attack the disease's 'Holy Grail"

Endpoints News: Backed with $180M-plus in cash, I/O trailblazer Lieping Chen spotlights NextCure's preclinical work on next-gen antibody

Nature: Protein-slaying drugs could be the next blockbuster therapies

Nature Reviews: First targeted protein degrader, developed by Arvinas, hits the clinic

Nasdaq: Cancer biotech Arvinas prices upsized IPO at $16

Tim Shannon: More hope for cystic fibrosis treatment, and still more to do

Scientific American: New thalidomide-like therapy hijacks cells’ trash-disposal system

Fierce Biotech: Mackay’s Rallybio rare disease startup raises $37M in first funding round

IDEAYA & the Next Frontier in Synthetic Lethality

FierceBiotech: GV, Roche help Ideaya to $94M crossover round, setting stage for synthetic lethality, I-O trials

FierceBiotech: Arvinas in $830M-plus Pfizer biobucks deal

BioCentury Innovations: How Vivace turns the YAP pathway off or on to treat cancer

Endpoints News: Genentech inks $650M deal with protein degradation pioneer Arvinas

Fierce Biotech: Canaan unveils $800 million fund for fresh wave of biotech bets

Fierce Biotech: Vivace uncloaks with $40M, U.S./China backing for cancer trials

Endpoints: Canaan reels in a jumbo $800 million with a big focus on a new wave of startups

STAT: Forget the science. These investors think they can pick biotech winners by algorithm

Tim Shannon: Durable bonds and the birth of Vivace Therapeutics